Project Grant R01AI184416
Award Date
12/1/24
Completion Date
11/30/29
Dollars Obligated
$767K
Federal Agency
National Institute of Allergy and Infectious Diseases
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Bronx, NY 10461, USA
Similar Awards
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $1,350,312 to develop a rapid phenotypic drug susceptibility testing system for tuberculosis (TB). The key products/services being delivered include: Developing and optimizing novel fluorescent trehalose probes (3HC-TRE and RMR-TRE) that can specifically detect live Mycobacterium tuberculosis (MTB) and...
The federal Project Grant award of $647,922.00, provided by the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research program), supports the development of a clinical decision support tool to optimize the selection of antibiotics for patients with rifampicin-resistant tuberculosis (RR-TB). The project aims to leverage spatiotemporal machine learning and decision models to synthesize data from clinical trials, local surveillance systems, and...
This federal Project Grant award, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a $201,549 study focused on understanding the metabolic profiles and outcomes of tuberculosis (TB) patients in Tanzania. The key goals of the study are to: 1) measure and characterize a range of metabolic markers and TB severity at the time of TB diagnosis, and 2) evaluate metabolic outcomes at the...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $843,516 to Vanderbilt University Medical Center (VUMC) to conduct clinical pharmacology research on short-course rifapentine for tuberculosis (TB) prevention. The key objectives are to: 1) confirm that model-informed doses of TB and HIV drugs achieve target exposures in priority populations like people living with...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $265,650 to support research focused on developing novel medicinal chemistry strategies to overcome drug-resistant tuberculosis (TB). The primary goal is to establish the structure-activity relationship and mechanism of action of a series of C25-modified rifabutin analogs that have demonstrated potent...
This federal Project Grant award, with ID R56AI180517, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The $749,414 grant, awarded on August 1, 2024, supports research to understand the role of the macrophage drug efflux pump MDR1 in Mycobacterium tuberculosis (M.TB) pathogenesis and explore whether targeting MDR1 can shorten tuberculosis (TB) treatment duration. The key research aims...
This $166,541 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will support the RADIANT-MOMS study. The study aims to examine preferences among pregnant and breastfeeding people, as well as healthcare providers, regarding novel shorter tuberculosis (TB) treatment regimens. The research will use qualitative and quantitative methods, including discrete choice experiments, to elicit...
This federal Project Grant award of $256,504 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) will fund a clinical trial to evaluate novel shortened treatment regimens for isoniazid-monoresistant tuberculosis (IMR-TB). The trial aims to compare the time to sputum culture conversion, safety, and relapse-free cure rates between the standard 6-month treatment regimen and two 4-month intervention regimens....
This Project Grant award of $193,375.00 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports a research project to investigate the impact of genetic variations in the ESX1 secretion system of Mycobacterium tuberculosis on drug treatment outcomes. The primary objectives are to use bacterial genetic approaches to assess the effects of clinically prevalent ESX1 variants on system function in vitro,...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on developing pro-apoptotic drugs as host-directed treatments for pulmonary tuberculosis (TB). The $774,881 award will support research to understand how pro-apoptotic drugs, such as navitoclax, can be used to shorten TB treatments and prevent post-TB lung disease. The researchers will leverage advanced...